A Study of TCB-CEA Bispecific Antibody for Locally Advanced and/or Metastatic CEA Positive Tumors.

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

The purpose of this study is to find out which doses of the study drug are safe to give to patients with gastrointestinal (colon, liver, pancreas, stomach) solid tumors. The study drug is RO6958688. RO6958688 is an antibody that targets CEA on the tumor cells and may activate the immune system in targeting cancer cells. The study will also explore how the study drug works in the body and on the tumor. The study also wants to find out if RO6958688 can slow down the growth of tumors or stop the cancer.

Are you Eligible? (Inclusion Criteria)

Patients must have colon cancer.

Specialty Area(s)


Trial Location

Columbia University Medical Center
Herbert Irving Pavilion
161 Fort Washington Avenue, 8th Floor
New York, NY 10032
United States